Julie Veziant

TL;DR: The possible links between the bacterial microbiota and colorectal carcinogenesis are discussed, focusing on dysbiosis and the potential pro-carcinogenic properties of bacteria, such as genotoxicity and other virulence factors, inflammation, host defenses modulation, bacterial-derived metabolism, oxidative stress and anti-oxidative defenses modulation.

TL;DR: The new microbiota-targeting strategies, such as probiotics and prebiotics, antibiotics, fecal microbiota transplantation and physical activity, which could be effective adjuvant therapies developed in order to improve anticancer therapeutic efficiency are described.

TL;DR: The microbial signatures associated with CRC known to date, including dysbiosis and faecal metabolome alterations, and the potential use of microbial variation markers for non-invasive early diagnosis and/or prognostic assessment of CRC and advanced adenomas are discussed.

TL;DR: The findings suggest that CoPEC could promote a procarcinogenic immune environment through impairment of antitumor T‐cell response, leading to tumoral resistance to immunotherapy, and could be a new biomarker predicting the anti‐PD‐1 response in CRC.

TL;DR: Data showed that infection with the pathogenic E. coli strain enhanced inflammation and ROS production in tumors before tumor growth, providing tools to better understand host-pathogen interactions at the early stage of disease, such as inflammatory bowel disease and colorectal cancer.